Sangamo BioSciences, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (DNA)-binding proteins (ZFPs), a naturally occurring class of proteins. ZFPs can be engineered to make ZFP nucleases (ZFNs), proteins that can be used to modify DNA sequences in a variety of ways and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. The main focus for its Company is the development of human therapeutics and it is building a pipeline of ZFP Therapeutics. Its lead ZFP Therapeutic, SB-728-T, a ZFN-modified autologous T-cell product for the treatment of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), is the first therapeutic application of its ZFN technology and is being evaluated in an ongoing Phase 11 and two Phase I/II clinical trials.